Cinclus Pharma
19,898
SEK
+0,16 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
+0,16%
-23,4%
-34,97%
-
-
-
-
-
-38,97%
cincluspharma.com/sv
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
CINPHA
Daglig lav / høj pris
19,116 / 20,27
SEK
Markedsværdi
926,01 mio. SEK
Aktieomsætning
1,02 mio. SEK
Volumen
51 t
Finanskalender
Årsrapport
20.02.2025
Delårsrapport
19.05.2025
Generalforsamling
22.05.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Trill Impact Ventures Pharma 1 | 8,0 % | 8,0 % |
| Fjärde AP-fonden | 7,9 % | 7,9 % |
| Futur Pension | 6,4 % | 6,4 % |
| Linc AB | 5,0 % | 5,0 % |
| Peter Unge | 4,4 % | 4,4 % |
| Kjell Andersson | 4,1 % | 4,1 % |
| Mikael Dahlströms Dödsbo | 4,0 % | 4,0 % |
| Movestic Life Insurance AB | 3,8 % | 3,8 % |
| Lennart Hansson through company | 2,3 % | 2,3 % |
| Irrus Investments | 2,1 % | 2,1 % |
ViserAlle indholdstyper
Redeye: Cinclus Pharma Q3 - Progress in preparations ahead of pivotal study
Interim Report January – September 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools